Boev S S
Ter Arkh. 1998;70(12):17-9.
To examine the impact of fenigidin treatment regimen on peripheral hemodynamics in patients with stable angina pectoris of effort and postinfarction cardiosclerosis without signs of heart failure.
Thirty two patients with functional classes II and III stable angina of effort and 32 with postinfarction cardiosclerosis without signs of heart failure were examined.
Monotherapy with fenigidin, 30-40 mg/day in patients with stable angina pectoris of effort and in those with postinfarction cardiosclerosis lowered systolic and mean blood pressures, total and specific peripheral vascular resistance, venous tone and increased additional venous volume and maximum vein emptying rate in the upper and lower extremities. Fenigidin therapy caused no side effects.
Fenigidin monotherapy improves hemodynamic parameters in stable angina pectoris of effort and postinfarction cardiosclerosis without obvious signs of heart failure and causes no side effects when the drug is used in a dose of 30-40 mg/day for 3 weeks.
研究非尼吉定治疗方案对劳力性稳定型心绞痛和心肌梗死后心硬化且无心力衰竭迹象患者外周血流动力学的影响。
对32例II级和III级劳力性稳定型心绞痛患者以及32例无心力衰竭迹象的心肌梗死后心硬化患者进行了检查。
非尼吉定单药治疗,剂量为30 - 40毫克/天,用于劳力性稳定型心绞痛患者和心肌梗死后心硬化患者时,可降低收缩压和平均血压、总外周血管阻力和特异性外周血管阻力、静脉张力,并增加上下肢额外静脉容量和最大静脉排空率。非尼吉定治疗未引起副作用。
非尼吉定单药治疗可改善劳力性稳定型心绞痛和心肌梗死后心硬化且无明显心力衰竭迹象患者的血流动力学参数,且当药物以30 - 40毫克/天的剂量使用3周时不会引起副作用。